miR-342-5p/AnkG Pathway in Early AD Synaptic Dysfunction

The Fourth Affiliated Hospital of Zhejiang University School of Medicine

Status: Enrolling

Conditions: Biomarker in Early Diagnosis; Alzheimer Disease

Treatments: Other: Collect peripheral blood, and if the patient consents, also collect cerebrospinal fluid.

Study type: Interventional

Funder types: Other

Identifiers

NCT07353502

KY-2025-070

Details and patient eligibility

About

Alzheimer's disease is the most common memory loss disease among the elderly. This disease affects the patient's memory, language, attention, and behavioral abilities. Current research has found that in the early stages of the disease, synaptic connections between brain nerve cells become abnormal, but the specific cause is still unclear. Investigators' previous research discovered that in the brains of diseased mice, certain special substances (the miR 342 5p/AnkG-mediated pathway) might be related to this abnormality, and these substances can be detected in both blood and cerebrospinal fluid. Therefore, investigators want to further explore the specific mechanisms of abnormal nerve cell connections, seek biomarkers for early detection of the disease, and provide new ideas for early diagnosis in the future.

Enrollment: 40 estimated patients

Sex: All

Ages: 50+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

Inclusion criteria for AD group:

1. Meet the diagnostic criteria for "probable AD dementia" established by the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA)
2. MMSE score between 0-23 points, Clinical Dementia Rating (CDR) score ≥0.5 points, Hachinski Ischemic Score <4 points
3. Brain MRI showing bilateral temporal lobe and hippocampal atrophy
4. Age ≥50 years

Inclusion criteria for control group:

1. Healthy subjects with age matched to the AD group
2. Normal cognitive function and good activities of daily living
3. No dementia patients among first-degree relatives
4. Negative brain MRI and neurological examination

Exclusion criteria

1. Dementia or cognitive impairment caused by other diseases
2. History of substance abuse
3. Progressive primary aphasia
4. Previous traumatic brain injury
5. Patients with comorbid depression, schizophrenia, or severe diseases of the cardiovascular, hepatic, renal, or hematological systems
6. Impaired consciousness and inability to cooperate
7. Other conditions unsuitable for inclusion

Trial design

Primary purpose: Diagnostic

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

40 participants in 2 patient groups

AD Group

Experimental group

Description:

Alzheimer's disease patients, collect peripheral blood, and if the patient agrees, also collect cerebrospinal fluid.

Treatment:

Other: Collect peripheral blood, and if the patient consents, also collect cerebrospinal fluid.

Healthy control group

Other group

Description:

Healthy control, collect peripheral blood, and if the patient agrees, also collect cerebrospinal fluid.

Treatment:

Other: Collect peripheral blood, and if the patient consents, also collect cerebrospinal fluid.